tiprankstipranks
Biosyent Inc (TSE:RX)
:RX
Canadian Market
Want to see TSE:RX full AI Analyst Report?

Biosyent (RX) Price & Analysis

53 Followers

RX Stock Chart & Stats

C$14.80
C$0.00(0.00%)
At close: 4:00 PM EST
C$14.80
C$0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
High ProfitabilitySustained high gross and operating margins indicate durable product-level economics and pricing power from in-licensed therapies. Strong margins support reinvestment into commercialization, partner payments and improve resilience to pricing pressure, bolstering long-term cash generation and ROE.
Conservative Balance SheetExtremely low leverage provides meaningful financial flexibility for licensing deals, working capital swings and opportunistic M&A, while minimizing refinancing risk. This enhances durability through industry cycles and supports steady operational funding without heavy interest burden.
Strong Cash GenerationOperating cash flow consistently exceeding net income and a sharp FCF rebound show high earnings quality and real cash conversion. Reliable cash generation underpins funding for partner milestones, commercialization investment, dividends or buybacks and reduces reliance on external financing.
Bears Say
Uneven Revenue CadenceRevenue has been lumpy historically, reflecting reliance on timing of in-licensed product launches and renewals. This uneven top-line makes forecasting and multi-period growth assumptions less certain, potentially increasing funding timing risk for commercialization investments and partner payouts.
FCF VolatilityMaterial swings in free cash flow, driven by working capital or investment timing, reduce predictability of internally available funds. For a small commercial model that pays partner fees or milestones, volatility can constrain the pace of new licensing deals or necessitate short-term financing in weaker quarters.
Concentration & Partnership RiskBusiness depends on in-licensed products and partner contracts; limited disclosure on partner terms or product concentration raises risk that loss or underperformance of a few products could materially impact revenue and margins, reducing long-term predictability of cash flows.

Biosyent News

RX FAQ

What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$10.65 and its highest was C$15.80 in the past 12 months.
    What is Biosyent Inc’s market cap?
    Biosyent Inc’s market cap is C$157.52M.
      When is Biosyent Inc’s upcoming earnings report date?
      Biosyent Inc’s upcoming earnings report date is Aug 25, 2026 which is in 76 days.
        How were Biosyent Inc’s earnings last quarter?
        Biosyent Inc released its earnings results on May 14, 2026. The company reported C$0.2 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.2.
          Is Biosyent Inc overvalued?
          According to Wall Street analysts Biosyent Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Biosyent Inc pay dividends?
            Biosyent Inc pays a Quarterly dividend of C$0.055 which represents an annual dividend yield of 1.6%. See more information on Biosyent Inc dividends here
              What is Biosyent Inc’s EPS estimate?
              Biosyent Inc’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Biosyent Inc have?
              Biosyent Inc has 11,497,447 shares outstanding.
                What happened to Biosyent Inc’s price movement after its last earnings report?
                Biosyent Inc reported an EPS of C$0.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.07%.
                  Which hedge fund is a major shareholder of Biosyent Inc?
                  Currently, no hedge funds are holding shares in TSE:RX
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Biosyent Inc

                    BioSyent Inc. is a specialized pharmaceutical enterprise operating both within Canada and internationally. The company is actively involved in identifying, obtaining, developing, and commercializing a diverse portfolio of pharmaceutical and health-related products. Among its offerings are iron supplements such as FeraMAX 150, FeraMAX Powder (a water-soluble oral iron solution promoting red blood cell formation), and FeraMAX Pd Therapeutic 150, all designed to prevent and manage iron deficiency anemia. BioSyent also provides Cathejell, utilized for surface anesthesia and lubrication during various medical procedures including cystoscopy, catheterization, endoscopy, and tracheal intubation, as well as for symptomatic relief of pain associated with cystitis and urethritis. Other key products include RepaGyn, a vaginal suppository aimed at healing vaginal mucosa and alleviating dryness caused by factors like menopause, stress, and chemotherapy, and Proktis-M, a rectal suppository supporting the healing of the anal and rectal areas. Furthermore, its lineup features Combogesic for reducing moderate acute pain and fever in adults, Protect-It, a non-chemical, food-safe grain insecticide used to prevent insect infestations in stored grains, and Tibella, a hormone replacement therapy addressing vasomotor symptoms stemming from estrogen deficiency. The company distributes its products through wholesalers and retail pharmacy chains. Headquartered in Mississauga, Canada, BioSyent Inc. was incorporated in 2006, having previously operated as Hedley Technologies Inc. before rebranding in June 2006 to emphasize its strategic focus on the pharmaceutical sector.

                    Biosyent (RX) Earnings & Revenues

                    RX Stock 12 Month Forecast

                    Average Price Target

                    C$18.00
                    ▲(21.62% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"C$9","14":"C$14","19":"C$19","11.5":"C$11.5","16.5":"C$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,11.5,14,16.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.05,14.353846153846154,14.657692307692308,14.961538461538462,15.265384615384615,15.569230769230769,15.873076923076923,16.176923076923078,16.48076923076923,16.784615384615385,17.088461538461537,17.392307692307693,17.696153846153845,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.05,14.353846153846154,14.657692307692308,14.961538461538462,15.265384615384615,15.569230769230769,15.873076923076923,16.176923076923078,16.48076923076923,16.784615384615385,17.088461538461537,17.392307692307693,17.696153846153845,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.05,14.353846153846154,14.657692307692308,14.961538461538462,15.265384615384615,15.569230769230769,15.873076923076923,16.176923076923078,16.48076923076923,16.784615384615385,17.088461538461537,17.392307692307693,17.696153846153845,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.368,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.614,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.201,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.929,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.425,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.872,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.634,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.406,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.678,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.741,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.253,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.05,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Aequus Pharmaceuticals
                    Willow Biosciences Inc
                    Medexus Pharmaceuticals Inc
                    HLS Therapeutics Inc
                    Cardiol Therapeutics

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks